Your browser doesn't support javascript.
loading
Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.
Waks, Adrienne G; Ogayo, Esther R; Paré, Laia; Marín-Aguilera, Mercedes; Brasó-Maristany, Fara; Galván, Patricia; Castillo, Oleguer; Martínez-Sáez, Olga; Vivancos, Ana; Villagrasa, Patricia; Villacampa, Guillermo; Tarantino, Paolo; Desai, Neelam; Guerriero, Jennifer; Metzger, Otto; Tung, Nadine M; Krop, Ian E; Parker, Joel S; Perou, Charles M; Prat, Aleix; Winer, Eric P; Tolaney, Sara M; Mittendorf, Elizabeth A.
  • Waks AG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Ogayo ER; Harvard Medical School, Boston, Massachusetts.
  • Paré L; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.
  • Marín-Aguilera M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Brasó-Maristany F; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.
  • Galván P; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
  • Castillo O; Reveal Genomics, Barcelona, Spain.
  • Martínez-Sáez O; Reveal Genomics, Barcelona, Spain.
  • Vivancos A; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
  • Villagrasa P; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
  • Villacampa G; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
  • Tarantino P; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
  • Desai N; Cancer Genomics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Guerriero J; Reveal Genomics, Barcelona, Spain.
  • Metzger O; Reveal Genomics, Barcelona, Spain.
  • Tung NM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Krop IE; Harvard Medical School, Boston, Massachusetts.
  • Parker JS; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.
  • Perou CM; Harvard Medical School, Boston, Massachusetts.
  • Prat A; Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Winer EP; Harvard Medical School, Boston, Massachusetts.
  • Tolaney SM; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.
  • Mittendorf EA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
JAMA Oncol ; 9(6): 835-840, 2023 06 01.
Article en En | MEDLINE | ID: mdl-37103927
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2023 Tipo del documento: Article